New GPR133 Receptor Discovery Offers Breakthrough Osteoporosis Treatment
- Researchers have identified a cell receptor that may serve as a biological switch to rebuild and protect bone density, potentially offering a new method to treat and reverse...
- The study, led by scientists from the University of Leipzig in Germany and Shandong University in China, identifies the receptor GPR133—also known as ADGRD1—as a powerful regulator of...
- By activating this receptor with a recently identified compound called AP503, researchers were able to increase bone density in mice and counteract damage similar to osteoporosis.
Researchers have identified a cell receptor that may serve as a biological switch to rebuild and protect bone density, potentially offering a new method to treat and reverse osteoporosis.
The study, led by scientists from the University of Leipzig in Germany and Shandong University in China, identifies the receptor GPR133—also known as ADGRD1—as a powerful regulator of bone strength.
By activating this receptor with a recently identified compound called AP503, researchers were able to increase bone density in mice and counteract damage similar to osteoporosis.
The Role of GPR133 in Bone Health
GPR133 belongs to a family of adhesion G protein-coupled receptors (GPCRs). These receptors are located on the surface of cells and transmit signals that control various bodily processes.
The research indicates that GPR133 is essential for the formation and maintenance of strong bones. It operates via bone-building cells known as osteoblasts.
The importance of this receptor was highlighted through genetic testing in mice. When the GPR133 gene was absent or impaired by genetic changes, the mice developed weak bones and a loss of bone density at an early age, mirroring the symptoms of human osteoporosis.
Mechanism of the AP503 Compound
To test whether the receptor could be stimulated, researchers used AP503, a compound discovered through a computer-assisted screen.
In experimental models, AP503 acts as a biological button that stimulates osteoblasts to work more effectively. When the receptor was present and activated by this compound, bone production and overall strength improved.
Ines Liebscher, University of Leipzig biochemist
Using the substance AP503, which was only recently identified via a computer-assisted screen as a stimulator of GPR133, we were able to significantly increase bone strength in both healthy and osteoporotic mice
The study also demonstrated that the effects of AP503 could work in tandem with exercise to further strengthen bones.
Clinical Implications for Osteoporosis
Osteoporosis is a condition that weakens bones, making them more susceptible to fractures. In Germany, the condition affects approximately six million people, with a high prevalence among women, particularly during aging and after menopause when bone density naturally declines.
Because current treatments may have limitations or side effects, the identification of GPR133 provides a new biological target for medication development.
The findings suggest a potential for treatments that do not only prevent further bone loss but could actually rebuild bones that have already been weakened.
Research Limitations and Future Outlook
While the results are promising, the researchers noted that these findings are based on animal models. However, they stated that the underlying biological processes are likely similar in humans.
The 2025 study opens the possibility for a new class of pharmacology focused on the specific subgroup of adhesion GPCRs, which have not been as widely studied as other receptors in medicine.